Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459468 · ClinicalTrials.gov registry record
Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
A clinical trial of Hepatocellular Carcinoma, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 17
- Enrollment target
- 1
- Study location
NCT04459468 is a study of Hepatocellular Carcinoma that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 17 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04459468, a study of Hepatocellular Carcinoma, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatment procedure for biomarker identification using bead based X-aptamer library. No intervention is planned.
Conditions Studied
Interventions
- DRUG Lipiodol
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2025-09-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04459468
The ClinicalTrials.gov registry entry for NCT04459468 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (93% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Lipiodol is the first listed.
NCT04459468 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04459468 about?
NCT04459468 is a clinical study titled "Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC". This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatment procedure for biomarker identification using bead based X-aptamer library. No intervention is plan...
What is the current status of trial NCT04459468?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2022-11-04. Estimated completion is 2025-09-23.
What conditions does trial NCT04459468 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT04459468?
The interventions under investigation include: Lipiodol (DRUG).
Who is sponsoring clinical trial NCT04459468?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04459468 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.